Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Joel GuigayKeun-Wook LeeManish R PatelAmaury DasteDeborah J WongSanjay GoelMichael S GordonMartin GutierrezAni BalmanoukianChristophe Le TourneauAlain MitaDamien VansteeneUlrich KeilholzPatrick SchöffskiHans Juergen GroteDongli ZhouMarcis BajarsNicolas PenelPublished in: Journal for immunotherapy of cancer (2022)
Avelumab showed clinical activity and was associated with a low rate of grade ≥3 TRAEs in heavily pretreated patients with platinum-refractory/ineligible R/M SCCHN.